Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

Over the past 15 years, rapid progress has been made in developmental therapeutics,
especially regarding the use of matched targeted therapies against specific oncogenic …

Background Standard first-line chemotherapy for endometrial cancer is paclitaxel plus
carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear …

Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly
as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the …

Abstract cGAS-STING pathway, as an essential intracellular immune response pathway, has
attracted much attention in tumor immunotherapy. However, low metabolic stability of …

Immune-checkpoint inhibitors show promising effects in the treatment of multiple tumor
types. Biomarkers are biological indicators used to select patients for a systemic anticancer …

Abstract The “hotness” or “coldness” of the tumors are determined by the information of the
cancer cells themselves, tumor immune characteristics, tumor microenvironment, and …

Endometrial cancer (EC) is one of the most common gynecological malignancies in Western
countries. Traditionally, loco-reginal dissemination and histological characteristics are the …

(1) Background: The oncology field has drastically changed with the advent of precision
medicine, led by the discovery of druggable genes or immune targets assessed through next …

Microsatellite instability (MSI) has been identified in several tumors arising from either
germline or somatic aberration. The presence of MSI in cancer predicts the sensitivity to …